BCAX
Bicara Therapeutics Inc.
$28.99
-1.41 (-4.64%)
At close · Jul 8
Market Cap
$1.95B
Shares
65,703,866
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$28.99
Open$30.25
Day$28.05–30.50
52W$8.98–30.99
Avg vol 30d846K
Short int10.2M · 15.5% float · 19.8d
Short vol62%
Last earningsMay 11, 2026
DataSep 2024–Jul 2026
Filing10-Q · May 11
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+54%
above
Price vs 50-day avg
+26%
above
RSI (14)
69
neutral
MACD trend
Positive
52-week position
91%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+44%
trailing
6-month return
+65%
trailing
YTD return
+72%
this year
Relative strength
+58%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $23 › 200d $19 — 50d above 200d
Institutional flow
Distributing
4 of 147 funds reported for Jun 30 · net -10.3K sh shares
Insider flow
Distributing
Net -$1.7M over 90 days · 100% sells
Short interest
Rising
15.46% of float · ▲ +0.8% MoM · 19.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
147 holders — near 1-yr high, broad support
Squeeze score
90
high risk · 0–100
Fundamentals
EPS growth
+38%
Y/Y
Free cash flow
$-107.1M
Balance sheet
$96.7M
net cash
Quant / Vol
risk profile
Volatility
61%
annualized · 1-yr
Max drawdown
−26%
past year
ATR
5.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 10, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+54%
Bullish
Price vs 50-day avg
+26%
Bullish
RSI (14)
69
Neutral
MACD trend
Positive
Bullish
52-week position
91%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $23 › 200d $19 — 50d above 200d
Institutional flow
Distributing
4 of 147 funds reported for Jun 30 · net -10.3K sh shares
Insider flow
Distributing
Net -$1.7M over 90 days · 100% sells
Short interest
Rising
15.46% of float · ▲ +0.8% MoM · 19.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
147 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $9
Now $29 · 91%
52-wk high $31
vs 200-day avg +54%
vs 50-day avg +26%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCAX
this stock
Bicara Therapeutics Inc.
|
$1.95B | +72.3% | — | — | 15.5% |
|
ONC
BeOne Medicines Ltd.
|
$437.67B | -0.6% | +22179.2% | 890.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.01B | +9.9% | +46.2% | 29.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.03B | -14.0% | +20.8% | 16.3 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCAX | -2.4% | +44.2% | +65.4% | -2.4% | +72.3% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -2.2% | +43.4% | +57.9% | -2.2% | +62.9% |